02019nas a2200385   4500000000100000008004100001653001300042653001700055653002400072653002500096653004200121653003900163653001100202653001800213653002000231653001400251653001300265653003000278653002600308653001700334653002600351653001000377653001500387100001100402700001600413700001200429700001300441700001200454700001100466245009700477300001100574490000700585520102700592022001401619       2005                            d10aTrachoma10aTetracycline10aSingle-Blind Method10aSecondary Prevention10aRandomized Controlled Trials as Topic10aOphthalmologic Surgical Procedures10aHumans10aHair Diseases10aEyelid Diseases10aEyelashes10aEthiopia10aCombined Modality Therapy10aChlamydia trachomatis10aAzithromycin10aAnti-Bacterial Agents10aAdult10aAdolescent1 aWest E1 aAlemayehu W1 aMunoz B1 aMelese M1 aImeru A1 aWest S00aSurgery for trichiasis, antibiotics to prevent recurrence (STAR) clinical trial methodology.  a279-860 v123 a<p>Trachoma is the leading infectious cause of blindness worldwide. Surgery is available to correct trichiasis, which results from repeated episodes of infection with C. trachomatis. However, trichiasis recurrence rates post-surgery are very high. Methods for reducing post-surgical trichiasis recurrence need to be explored. This paper outlines the design of the Surgery for Trichiasis, Antibiotics to prevent Recurrence (STAR) Clinical Trial currently underway in Ethiopia. The STAR trial, funded by The National Eye Institute, is a randomized, controlled clinical trial of antibiotic use at time of trichiasis surgery, comparing topical tetracycline to single-dose azithromycin for the surgical patient and single-dose azithromycin for the surgical patient and all household members. The primary outcome is trichiasis recurrence at one-year. Data from this trial will be critical in helping to determine future policy on antibiotic treatment for C. trachomatis following surgery.</p>

<p>&nbsp;
<p>&nbsp;</p>
</p>
  a0928-6586